AstraZeneca PLC (AZN)vsKailera Therapeutics, Inc. Common Stock (KLRA)
AZN
AstraZeneca PLC
$157.24
-0.50%
HEALTHCARE · Cap: $243.86B
KLRA
Kailera Therapeutics, Inc. Common Stock
$17.94
-0.17%
HEALTHCARE · Cap: $2.19B
Smart Verdict
WallStSmart Research — data-driven comparison
AZN leads profitability with a 17.0% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 65/100 (B-).
AZN
Strong Buy65
out of 100
Grade: B-
KLRA
Avoid22
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+20.4%
Fair Value
$196.68
Current Price
$157.24
$39.44 discount
Intrinsic value data unavailable for KLRA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.40 suggests the stock is reasonably priced for its growth.
Bull Case : KLRA
The strongest argument for KLRA centers on Debt/Equity.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : KLRA
The primary concerns for KLRA are Revenue Growth, EPS Growth, Profit Margin.
Key Dynamics to Monitor
AZN profiles as a mature stock while KLRA is a value play — different risk/reward profiles.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (65/100 vs 22/100), backed by strong 17.0% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Kailera Therapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Kailera Therapeutics, Inc. is an innovative biotechnology company focused on pioneering gene therapies to address rare genetic diseases, leveraging advanced technologies to fulfill significant unmet medical needs. The firm’s proprietary platform enhances the precision and efficacy of its therapeutic solutions across a wide range of genetic disorders. With a robust intellectual property portfolio and strategic partnerships with leading research institutions, Kailera is well-positioned to establish itself as a frontrunner in the gene therapy landscape. As it advances its promising product pipeline, Kailera is dedicated to creating long-term value for investors while making impactful contributions to patient health.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?